GABA Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather AB (publ) was incorporated in 2014 and is based in Södertälje, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Gabather (STO: GABA)
›
Gabather (STO: GABA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.0188 SEK on 19 November 2026, down 39.4% over 52 weeks. Its 52-week range is 0.0162 SEK to 0.1000 SEK: the price is 81.2% below the high and 16.0% above the low.
Its market capitalisation is 11.48M SEK.
Gabather reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.69M SEK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.